Monthly information on share capital and company voting rights

Cellectis (Euronext Growth: CLLS) reports monthly share capital and voting rights as of January 31, 2026.

Rhea-AI Summary

Cellectis (Euronext Growth: CLLS) reports monthly share capital and voting rights as of January 31, 2026. The company lists 100,590,994 total shares and 105,825,481 total voting rights. ISIN: FR0010425595. Contact details provided for media and investors.

Argus Feb 5 session

-1.13% close to close Open Argus

Details

News Market Reaction – CLLS

In the Feb 5 session, CLLS declined 1.13%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement provides an updated snapshot of Cellectis’s capital structure, stating 100,590,994...

Analysis

This announcement provides an updated snapshot of Cellectis’s capital structure, stating 100,590,994 shares and 105,825,481 voting rights as of Jan 31, 2026. Similar monthly disclosures on Dec 3 and Jan 5 helped keep investors informed on potential dilution and control. Alongside an effective Form F-3 shelf and recent clinical and strategic updates, investors may track how future capital decisions interact with pipeline progress and market conditions.

Key Figures

Total shares: 100,590,994 Total voting rights: 105,825,481 Reference date: 01/31/2026

Total shares

100,590,994

Total number of shares in the capital as of 01/31/2026

Total voting rights

105,825,481

Total number of voting rights as of 01/31/2026

Reference date

01/31/2026

Date of share capital and voting rights information

Historical Context

5 past events · Latest: Jan 08

5 events

1. Jan 08

   Strategy and pipeline update

   24h Move

   -1.6%

   Outlined 2026 allogeneic CAR-T strategy and multiple clinical catalysts.

2. Jan 05

   Monthly share/votes report

   24h Move

   -5.4%

   Published December 31, 2025 share count and total voting rights.

3. Dec 15

   Arbitral decision

   24h Move

   +2.4%

   Reported partial termination of a Servier license for UCART19 V1.

4. Dec 08

   Clinical data update

   24h Move

   -2.5%

   Presented Phase 1 NATHALI-01 eti-cel data with high ORR and CR rates.

5. Dec 03

   Monthly share/votes report

   24h Move

   +3.6%

   Disclosed November 30, 2025 share count and voting rights.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

isin

1 terms

isin financial

"Listing market: Euronext Growth ISIN code: FR0010425595"

A 12-character International Securities Identification Number (ISIN) is a unique code that acts like a passport for a specific stock, bond or other tradable security so it can be identified worldwide. Investors and systems use it to ensure they are buying, selling and tracking the exact same instrument across exchanges and data feeds, which prevents costly mix-ups and makes portfolio reporting, settlement and regulatory checks simpler and more reliable.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, Feb. 04, 2026 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
01/31/2026	100,590,994	105,825,481

For further information on Cellectis, please contact:

Media contacts:

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:

Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com 

Attachment

• Voting_Rights_PR_January_2026_EN

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Cellectis (CLLS) have outstanding on January 31, 2026?

Cellectis reported 100,590,994 total shares outstanding as of January 31, 2026. According to Cellectis, this figure represents the company's registered share capital on that date for Euronext Growth reporting purposes.

What were Cellectis (CLLS) total voting rights on January 31, 2026?

Cellectis recorded 105,825,481 total voting rights on January 31, 2026. According to Cellectis, the voting rights total reflects shares carrying voting power, including double-vote or treasury share adjustments where applicable.

Where is Cellectis (CLLS) listed and what is its ISIN code?

Cellectis is listed on Euronext Growth and its ISIN code is FR0010425595. According to Cellectis, this listing and ISIN identify the company's securities for trading and regulatory disclosures in France.

Who should investors contact for more information about Cellectis (CLLS) shareholder data?

Investors can contact Arthur Stril, Chief Financial Officer & Chief Business Officer, via investors@cellectis.com. According to Cellectis, the investor relations contact handles questions on share capital and voting rights disclosures.

Does the January 2026 voting rights report for Cellectis (CLLS) include a detailed attachment?

Yes, the disclosure references an attachment named Voting_Rights_PR_January_2026_EN. According to Cellectis, the attachment contains the formal breakdown used for the monthly regulatory filing and investor review.